Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.

Materials And Methods: We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).

Results: Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.

Conclusion: The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582469PMC
http://dx.doi.org/10.4143/crt.2021.1083DOI Listing

Publication Analysis

Top Keywords

group iii
16
2005 2014
12
years group
12
pattern care
8
brain metastasis
8
metastasis breast
8
breast cancer
8
group
8
patients group
8
years
7

Similar Publications

Background: Gait impairment in Parkinson's disease (PD) occurs early and pharmaceutical interventions do not fully restore this function. Visual cueing has been shown to improve gait and alleviate freezing of gait (FOG) in PD. Technological development of digital laser shoe visual cues now allows for visual cues to be used continuously when walking.

View Article and Find Full Text PDF

The study investigated the impact of different treatments on recovery from calcaneal tendinopathy in rats, focusing on the gastrocnemius muscle. Tendinopathy is caused by repetitive overload, leading to structural collagen damage and chronic muscle inflammation. Three therapeutic approaches were compared: photobiomodulation (PBM), advanced platelet-rich fibrin (A-PRF) injection, and a combination of the two.

View Article and Find Full Text PDF

Hypersensitivity reactions to quinolones (QHRs) have been increasing in frequency, thus classifying them as the second most frequently implicated class of antibiotics in hypersensitivity reactions (HRs). It is noteworthy that quinolones (Qs) have been observed to predominantly trigger immediate hypersensitivity reactions (IHRs). These reactions are categorized as either IgE-mediated or non-IgE-mediated, attributable to the off-target occupation of the recently described receptor, Mas-related G-protein coupled receptor member X2 (MRGPRX2), on effector cells.

View Article and Find Full Text PDF

Background: Moderate to severe acne scars pose a therapeutic challenge and often require multimodal treatments. Ablative fractional laser (AFL) and fractional microneedling radiofrequency (FMR) are commonly used, but their alternating application has not been fully studied.

Patients And Methods: In this prospective, randomized, single-blind, split-face trial, 20 patients (Fitzpatrick III-IV) received four treatments at 4-week intervals: one facial side underwent alternating FMR (sessions 1, 3) and AFL (sessions 2, 4), while the contralateral side received AFL alone.

View Article and Find Full Text PDF

Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial.

J Dermatolog Treat

December 2025

Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.

Background: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).

Objectives: This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients.

Methods: Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed.

View Article and Find Full Text PDF